FDAnews
www.fdanews.com/articles/98228-iomai-begins-dosing-in-immunostimulant-patch-study

Iomai Begins Dosing in Immunostimulant Patch Study

September 7, 2007

Iomai announced that it has started dosing in a Phase I/II study that will assess the safety and dose-sparing capability of the company’s immunostimulant patch when used in combination with an injected H5N1 influenza vaccine.

According to Iomai, the patch, which contains an immune-stimulating adjuvant, is used in conjunction with an injected influenza vaccine and may generate an immune response with small amounts of vaccine antigen.

The study will enroll approximately 500 subjects who will receive either a placebo injection or one of three dosages of pandemic influenza vaccine. Patients will receive a booster shot of placebo or vaccine 21 days later.

Approximately one-third of the subjects will receive no immunostimulant patch, one-third will receive a patch only with the booster shot and one-third will receive a patch with both vaccine injections. Subjects will be followed for safety, and immune responses to the pandemic vaccine will be evaluated, the company said.